Q-omics provides the consensus-scored ZNF200 profile across patient tissues and cancer cell-line models. ZNF200 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF200 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ZNF200 RNA expression shows 20,816 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ZNF200 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF200 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF200 survival associations across molecular data types. ZNF200 RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF200 RNA expression–survival associations across cancer types. High ZNF200 expression shows unfavorable associations in ACC and LGG, but favorable associations in KIRC, SKCM, SCLC and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF200 RNA expression.
This table summarizes ZNF200 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF200. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF200 shows higher tumor expression in HNSC, COAD, KIRP, LIHC, KIRC and STAD. The HNSC box plot shows higher ZNF200 RNA expression in tumor versus normal tissue (log2 FC = +1.081, t-test p < 0.001).
This table shows molecular features associated with ZNF200 in patient tissues and cancer cell lines. In patient samples, ZNF200 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF200 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
